Schrodinger’s Strategic Collaborations and Financial Position Bolster Buy Rating Amid Market Confidence and Future Growth Potential
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on SDGR stock, giving a Buy rating yesterday. Mani Foroohar has ...
Crain's New York17h
Midtown-based drug company inks $150M deal with Novartis
Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...
Business Insider21h
Schrodinger price target raised to $28 from $27 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company’s Q3 results and announced deal with Novartis (NVS) involving ...